CSL to pump $1.5bn into US plasma supply chain
CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production,…
Immunology
-
-
Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
Backed by $70m in Series A funding, Elevara Medicines has launched to advance its CDK4/6 inhibitor, which belongs to a…
-
ESMO 2025: Hengrui’s immunotherapy combo shows perioperative benefit in HCC
On Saturday 19 October 2025, at the European Society for Medical Oncology (ESMO), held in Berlin, Germany, Hengrui presented results…
-
ERS 2025: Long-term CFTR use shows clinical benefit but variable microbial impact
At the 2025 European Respiratory Society (ERS) International Congress taking place in Amsterdam, the Netherlands, from 27 September to 1…
-
ERS 2025: APG808 to address need for biologic for moderate asthma
At the 2025 European Respiratory Society (ERS) International Congress takig place in Amsterdam, the Netherlands, from 27 September to 1…
-
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton…
-
FUJIFILM Biotechnologies and argenx expand global partnership
FUJIFILM Biotechnologies has expanded its global partnership with immunology company argenx to manufacture the latter’s drug substance for efgartigimod at…
-
aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary…
-
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal…
-
AbbVie extends Rinvoq exclusivity by four years after generics settlements
AbbVie has bolstered the sales outlook of its blockbuster autoimmune drug Rinvoq (upadacitinib) by extending its exclusivity until 2037. The…
